We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lifts Hold on Gilead Sciences’ Investigational HIV Drug Lenacapavir
FDA Lifts Hold on Gilead Sciences’ Investigational HIV Drug Lenacapavir
The FDA has removed a clinical hold it placed on Gilead Sciences’ experimental HIV-1 drug lenacapavir in December 2021 because of quality concerns about the drug’s borosilicate glass vials.